Bio Rad Laboratories Inc (NYSE:BIO)
| 797.31 Delayed Data As of Sep 23 |  +11.67 / +1.49%Today’s Change | 490.73 Today|||52-Week Range 832.70 | +36.77% Year-to-Date |
Latest BIO News | Press Releases
| Bio-Rad (BIO) Upgraded to Strong Buy: Here's Why Sep 16 / Zacks.com - Paid Partner Content | Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now Sep 13 / Zacks.com - Paid Partner Content |
| Bio-Rad Laboratories (BIO) Is Up 0.05% in One Week: What You Should Know Sep 14 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 785.64 |
| Today’s open | 789.97 |
| Day’s range | 789.97 - 801.65 |
| Volume | 102,061 |
| Average volume (3 months) | 125,781 |
| Market cap | $19.5B |
Data as of 3:59pm ET, 09/23/2021
Growth & Valuation
| Earnings growth (last year) | +116.97% |
| Earnings growth (this year) | +36.49% |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +10.12% |
| P/E ratio | 5.9 |
| Price/Sales | 6.91 |
| Price/Book | 2.38 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PKIPerkinElmer Inc | +0.99 | +0.53% |
| WATWaters Corp | +6.82 | +1.72% |
| QGENQiagen NV | +0.08 | +0.15% |
| BRKRBruker Corp | +1.46 | +1.75% |
Data as of 4:00pm ET, 09/23/2021
Financials
| Next reporting date | November 4, 2021 |
| EPS forecast (this quarter) | $2.44 |
| Annual revenue (last year) | $2.5B |
| Annual profit (last year) | $3.8B |
| Net profit margin | 149.52% |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Hercules, California |
Forecasts
